BBIXF (Bonus BioGroup) EBITDA Margin %: 0.00% (As of Dec. 2025)


BBIXF Bonus BioGroup Ltd BBIXF
30 GF Score
Price $0.11
! 3 Warning Signs
View Full Analysis

What is Bonus BioGroup EBITDA Margin %?

Bonus BioGroup BBIXF 30 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates BBIXF with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 937 Biotechnology companies, Bonus BioGroup ranks worse than 106723.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bonus BioGroup's EBITDA for the six months ended in Dec. 2025 was $-3.39 Mil. Bonus BioGroup's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Bonus BioGroup's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Bonus BioGroup  (OTCPK:BBIXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bonus BioGroup EBITDA Margin % Related Terms

Bonus BioGroup EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bonus BioGroup's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bonus BioGroup EBITDA Margin % Chart

Bonus BioGroup Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bonus BioGroup Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BBIXF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Bonus BioGroup's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bonus BioGroup EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bonus BioGroup's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bonus BioGroup's EBITDA Margin % falls into.


BBIXF
30GF Score
Bonus BioGroup Ltd BBIXF
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bonus BioGroup EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bonus BioGroup's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.988/0
= %

Bonus BioGroup's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.386/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bonus BioGroup (BBIXF) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonus BioGroup and its competitors. According to the industry distribution chart, Bonus BioGroup ranks #999999 out of 937 companies in the Biotechnology industry.
Is Bonus BioGroup's EBITDA Margin % too high?
Bonus BioGroup's current EBITDA Margin % is 0.00%. Based on the distribution chart, Bonus BioGroup ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bonus BioGroup has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bonus BioGroup's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bonus BioGroup ranks #999999 out of 937 companies for EBITDA Margin %. This places Bonus BioGroup in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonus BioGroup and its competitors. Bonus BioGroup's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonus BioGroup stock overvalued right now?
Bonus BioGroup (BBIXF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Bonus BioGroup's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bonus BioGroup (BBIXF), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bonus BioGroup Business Description

Other Exchanges BONS:Israel
Address Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905
Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.
30GF Score

Get the complete analysis for BBIXF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price